Paolo Grumati | Cell Biology | Best Researcher Award

Prof. Paolo Grumati | Cell Biology | Best Researcher Award

Prof. Paolo Grumati,  TIGEM, Italy.

Dr. Paolo Grumati is a prominent researcher and academic with a focus on molecular biology, particularly the study of autophagy and its role in diseases such as muscular dystrophies and neurodegenerative disorders. His academic journey, beginning with a Master’s and Ph.D. from the University of Padova, laid the foundation for his pioneering work in the molecular mechanisms underlying disease pathogenesis. Dr. Grumati’s professional endeavors have included roles at esteemed institutions like Johann Wolfgang Goethe University and the Telethon Institute of Genetics and Medicine (TIGEM), where he leads groundbreaking research in selective autophagy. His work, which integrates advanced techniques like CRISPR/Cas9, has earned him widespread recognition and numerous accolades, including positions as Associate Professor at the University of Naples. His research has had a significant impact on the scientific community, particularly in the areas of cellular maintenance and therapeutic development.

Profile

Scopus

 

Early Academic Pursuits 🎓


Paolo Grumati’s academic journey began at the University of Padova in Italy, where he pursued a Master’s Degree in Medical Biotechnologies, graduating in 2005. His deep curiosity in the molecular underpinnings of human biology led him to continue his studies with a Ph.D. in Genetic and Molecular Biology, completed between 2006 and 2009. During his Ph.D., he focused on the genetic mechanisms that contribute to various diseases, a pursuit that sparked his lasting interest in molecular biology and disease pathogenesis. His early academic training laid a strong foundation for his future research in the biochemistry of diseases, especially those that affect muscle function and cellular processes.

Professional Endeavors 💼


Dr. Grumati’s professional career has been marked by an impressive trajectory across prestigious institutions. After completing his postdoctoral work on the pathogenesis of muscular dystrophies at the University of Padova, he moved to Germany, where he took a position at the Institute of Biochemistry II at Johann Wolfgang Goethe University. There, between 2013 and 2018, he specialized in the biochemistry and molecular biology of autophagy, a crucial cellular process related to health and disease. His expertise in autophagy became a defining element of his career, and in 2019, he was appointed as the Assistant Investigator and Head of the Mass Spectrometry Core at the Telethon Institute of Genetics and Medicine (TIGEM), where he leads innovative research into the molecular mechanisms of selective autophagy. Throughout these roles, Dr. Grumati has built a reputation for integrating advanced techniques like CRISPR/Cas9 into his work, influencing the field of genetic research.

Contributions and Research Focus 🔬


Dr. Grumati’s research focus has consistently revolved around the intricate molecular processes that govern cellular maintenance and disease, particularly through the lens of autophagy. Since becoming a principal investigator in 2019, his work at TIGEM has concentrated on understanding the molecular mechanisms of selective autophagy, which plays a pivotal role in cellular health and disease. He has pioneered methods to study and manipulate these processes, contributing significantly to the understanding of diseases such as muscular dystrophies and neurodegenerative disorders. His research not only delves into the underlying biology of these conditions but also seeks to identify therapeutic targets that could help manage or even cure these diseases.

Accolades and Recognition 🏆


Dr. Grumati has received widespread recognition for his work in molecular biology and biochemistry. His contributions to the field of autophagy and muscle biology have been honored with leadership roles in prominent research teams, including his time as Team Leader of the Frankfurt CRISPR/Cas9 Screening Center. His excellence in research has earned him a faculty position as Assistant Professor at the University of Naples “Federico II” and an eventual promotion to Associate Professor in 2024. His expertise in mass spectrometry and molecular biology has also made him a sought-after figure in the scientific community, where he is frequently invited to collaborate on interdisciplinary research projects.

Impact and Influence 🌍


Dr. Grumati’s research has had a lasting impact on the scientific community, particularly in the fields of autophagy and muscular dystrophies. His work has influenced both theoretical and applied aspects of molecular biology, from basic research to potential therapeutic interventions. Through his leadership at TIGEM and his involvement in international collaborations, Dr. Grumati has helped to shape the direction of research into autophagy-related diseases. His studies have not only provided insights into the cellular mechanisms at play in these diseases but also paved the way for future therapeutic strategies. He is seen as a key figure in the advancement of precision medicine and molecular therapeutics.

Legacy and Future Contributions 🔮

As Dr. Grumati moves forward in his career, his contributions to the fields of genetics and molecular biology are expected to have a profound and lasting influence. His current work, focusing on selective autophagy, holds promise for the development of novel treatments for diseases that currently have limited therapeutic options. His legacy will likely include innovations in understanding cellular degradation processes and their application to genetic disorders and other diseases. The future of Dr. Grumati’s research will continue to explore the molecular intricacies of human health, offering the potential for breakthroughs in regenerative medicine and disease treatment.

Teaching and Mentorship 👨‍🏫


Beyond his research, Dr. Grumati has made a significant impact through his academic roles at the University of Naples. As an Associate Professor, he plays a key role in shaping the next generation of molecular biologists. His teaching focuses on imparting knowledge in genetics, biochemistry, and molecular biology, with an emphasis on practical research applications. His mentorship has helped guide many students and early-career researchers, who have gone on to make their own contributions to the field. Dr. Grumati’s ability to translate complex scientific concepts into accessible lessons ensures that his influence extends far beyond his own research.

Publication

  • Title: Cortico-striatal circuit mechanisms drive the effects of D1 dopamine agonists on memory capacity in mice through cAMP/PKA signalling
    Authors: M. de Risi, D. Cavezza, G. Torromino, P. Grumati, E. de Leonibus
    Year: 2025

 

  • Title: Two FAM134B isoforms differentially regulate ER dynamics during myogenesis
    Authors: V. Buonomo, K.O. Lohachova, A. Reggio, R.M. Bhaskara, P. Grumati
    Year: 2025

 

  • Title: Ezrin defines TSC complex activation at endosomal compartments through EGFR-AKT signaling
    Authors: G. Giamundo, D. Intartaglia, E. del Prete, R. De Cegli, I. Conte
    Year: 2025

 

  • Title: 3D Rotary Wet-Spinning (RoWS) Biofabrication Directly Affects Proteomic Signature and Myogenic Maturation in Muscle Pericyte–Derived Human Myo-Substitute
    Authors: A. Reggio, C. Fuoco, F. de Paolis, M. Costantini, C. Gargioli
    Year: 2025

 

  • Title: Cross-Linking Mass Spectrometry to Capture Protein Network Dynamics of Cell Membranome
    Authors: L. Santorelli, M. Costanzo, S. Petrosino, M. Ruoppolo, P. Grumati
    Year: 2025

 

  • Title: Mitochondrial mechanotransduction through MIEF1 coordinates the nuclear response to forces
    Authors: P. Romani, G. Benedetti, M. Cusan, G. Martello, S. Dupont
    Year: 2024

 

Conclusion


Dr. Paolo Grumati’s career exemplifies the integration of scientific inquiry with practical application, as his research continues to shed light on crucial molecular processes that affect human health. His contributions to the understanding of autophagy have opened new avenues for potential therapeutic strategies in treating genetic disorders and other diseases. As he continues to lead research at TIGEM and teach at the University of Naples, Dr. Grumati’s legacy is set to influence the fields of molecular biology, genetics, and medicine for years to come. His work remains pivotal in advancing both the theoretical understanding of disease mechanisms and the development of new therapeutic approaches, positioning him as a key figure in modern biomedical research.

Rong Wang | Oncology | Best Researcher Award

Dr. Rong Wang | Oncology | Best Researcher Award

Dr. Rong Wang, Nanfang Hospital, Southern Medical University, China.

Dr. Rong Wang, a distinguished figure at Nanfang Hospital, Southern Medical University, has built an impressive career that bridges clinical excellence and pioneering research. From her early academic days, she showed a strong commitment to medical science, which translated into impactful professional endeavors in both patient care and research. Her primary focus lies in clinical and translational medicine, where she has made significant contributions through innovative diagnostics, treatment strategies, and interdisciplinary collaboration. Her accolades reflect her dedication, while her influence is evident in the global reach of her work and her role as a mentor and leader in the medical community.

Profile

Orcid

 

🎓 Early Academic Pursuits

Dr. Rong Wang began her academic journey with a strong foundation in medical sciences, reflecting a deep commitment to healthcare from an early stage. Her educational path was marked by excellence, as she pursued rigorous training in clinical medicine and specialized disciplines. Her formative years at esteemed institutions prepared her with a robust understanding of both theoretical and practical dimensions of medical research, setting the stage for a remarkable professional trajectory.

🏥 Professional Endeavors

Currently affiliated with Nanfang Hospital at Southern Medical University, China, Dr. Rong Wang has established herself as a dedicated clinician and researcher. Her work seamlessly integrates patient care with academic inquiry, creating a dynamic synergy between hospital-based practice and medical innovation. Her role at this prestigious institution has enabled her to engage in cutting-edge research, medical education, and multidisciplinary collaborations that enhance both her personal growth and the advancement of the medical field.

🔬 Contributions and Research Focus

Dr. Wang’s research interests are deeply embedded in clinical and translational medicine, particularly focusing on emerging healthcare challenges in China and globally. Her investigations often revolve around innovative diagnostic techniques, treatment protocols, and patient-centered care strategies. With a vision to bridge the gap between laboratory research and bedside application, her contributions have not only enriched scientific literature but also improved therapeutic outcomes.

🏅 Accolades and Recognition

Over the years, Dr. Rong Wang has been the recipient of numerous accolades that reflect her unwavering dedication to medicine and research. Her work has garnered respect from peers and institutions alike, earning her prestigious awards and invitations to speak at national and international conferences. These honors underscore her role as a thought leader and innovator in the field.

🌏 Impact and Influence

Dr. Wang’s influence extends beyond the walls of her hospital. Her research has informed public health policies and contributed to global discourses on health equity and innovation. She actively collaborates with other researchers and healthcare professionals to promote knowledge exchange, medical training, and sustainable healthcare models. Her mentorship has inspired a new generation of researchers and medical practitioners who are carrying forward her legacy of excellence and empathy.

🌟 Legacy and Future Contributions

As she continues to evolve in her career, Dr. Rong Wang remains committed to pioneering research and medical advancement. Her future aspirations include expanding her research on integrative healthcare solutions and influencing healthcare reform through evidence-based policies. Through her persistent efforts, she aims to leave a lasting legacy marked by innovation, compassion, and societal impact.

🧠 Research-Driven Innovation

At the core of Dr. Wang’s professional identity is her relentless pursuit of scientific truth and practical solutions. Her research embodies a spirit of curiosity and a drive to solve complex medical challenges. Whether through publishing in high-impact journals or leading clinical trials, she consistently pushes the boundaries of knowledge, aiming to bring transformative change to patient care and health systems.

publication

  • Title: Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR‐TKI Resistance
    Authors: Jingyi Wu, Xiangfei Wu, Jing Wang, Guili Feng, Yuhan Wang, Zide Chen, Wei Wang, Rong Wang
    Year: 2025

 

  • Title: Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
    Authors: Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto, et al.
    Year: 2020

 

🔚 Conclusion

With a future-oriented mindset and an unwavering commitment to advancing healthcare, Dr. Rong Wang stands as a beacon of medical innovation and compassion. Her career is a testament to how scientific research and clinical practice can come together to improve lives and shape the future of medicine. As she continues her journey, her legacy will be defined by her transformative contributions, the people she has inspired, and the advancements she has helped bring to life in the world of healthcare.

Dinh Phong Son | CircRNA | Best Researcher Award

Dr. Dinh Phong Son | CircRNA | Best Researcher Award

Dr. DINH PHONG SON, DUYTAN UNIVERSITY, Vietnam.

Dr. Dinh Phong Son is a researcher specializing in laboratory medicine techniques with a Ph.D. in Molecular Medicine from Guangxi Medical University, China. His research focuses on modern molecular biology techniques, particularly the identification of potential biomarkers for early disease diagnosis and targeted therapy. His studies explore systemic diseases such as diabetes, cardiovascular diseases, and cancer, emphasizing gene editing technologies like CRISPR/Cas9. His recent publications contribute to the understanding of regulatory RNA networks and their implications in disease mechanisms, providing a foundation for future studies on molecular interactions and targeted drug development.

Profile

Orcid

 

🎓 Early Academic Pursuits

From the very beginning of my academic journey, I was deeply fascinated by the intricate mechanisms of life at a molecular level. My pursuit of knowledge led me to study Laboratory Medicine Technique at Hue University of Medicine and Pharmacy, Vietnam, where I honed my expertise in diagnostic methodologies and medical laboratory sciences. With an insatiable thirst for discovery, I furthered my education by earning a Doctorate (Ph.D.) in Molecular Medicine from Guangxi Medical University, China. This academic foundation set the stage for my dedication to the field of molecular biology, shaping my vision to explore genetic markers and innovative diagnostic tools.

👩‍🎓 Professional Endeavors

Currently, I serve at Duy Tan University, College of Medicine and Pharmacy, where I actively contribute to research, mentoring, and academic discourse. My work primarily revolves around molecular diagnostics, genetic analysis, and disease biomarker identification, aiming to bridge the gap between molecular biology and clinical applications. With advancements in next-generation sequencing (NGS) and bioinformatics databases, I continually seek new pathways to enhance the precision of disease detection and treatment strategies.

🧪 Contributions and Research Focus

My research is deeply rooted in molecular medicine, focusing on the identification of potential biomarkers for the early diagnosis of systemic diseases such as diabetes, cardiovascular diseases, stroke, and cancer. My investigations also extend to exploring gene targets for pharmacological studies, assisting in drug development through the modulation of gene expression using cutting-edge technologies like CRISPR/Cas9, gene overexpression, and silencing approaches. Furthermore, my work delves into the complex LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks, paving the way for theoretical models that could revolutionize targeted therapy research.

 

💎 Impact and Influence

The impact of my research extends beyond academia, as it plays a crucial role in early disease screening, personalized medicine, and therapeutic advancements. By leveraging molecular networks, I aim to facilitate the development of precise diagnostic tools and gene-targeted interventions, significantly improving patient outcomes. My research findings have the potential to reshape biomedical applications and create avenues for innovative treatment strategies across various diseases.

🌟 Legacy and Future Contributions

Looking ahead, my aspirations remain steadfast in expanding molecular biology research, particularly in uncovering novel biomarkers and refining gene-editing techniques. As the field continues to evolve, I hope to contribute to the refinement of therapeutic gene modifications and biomarker-based diagnostics. With sustained efforts and collaborations, I envision a future where my research serves as a cornerstone for breakthroughs in precision medicine, targeted gene therapy, and advanced molecular diagnostics.

👨‍💼 Professional Collaborations and Memberships

As an active member of the scientific community, I engage in collaborations and professional affiliations to foster knowledge exchange and multidisciplinary research. My involvement in editorial appointments, consultancy projects, and industry partnerships enables me to extend my research impact, ensuring that molecular medicine continues to advance for the benefit of humanity.

 

Publication

  • Title: Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on Microarray Data analysis, molecular docking, and dynamic simulation
    Authors: PhongSon Dinh, ChauMyThanh Tran, ThiPhuongHoai Dinh, Hai-Anh Ha, Aigul Utegenova, Awais Ali, Abdulaziz Alamri
    Year: 2025

 

  • Title: Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1
    Authors: PhongSon Dinh, ChauMyThanh Tran, ThiPhuongHoai Dinh, Awais Ali, ShangLing Pan
    Year: 2024

 

  • Title: Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data
    Authors: ChauMyThanh Tran, PhongSon Dinh
    Year: 2024

 

  • Title: Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease
    Authors: PhongSon Dinh, JunHua Peng, ThanhLoan Tran, DongFeng Wu, ChauMyThanh Tran, ThiPhuongHoai Dinh, ShangLing Pan
    Year: 2023

 

  • Title: Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis
    Authors: PhongSon Dinh, Jun-Hua Peng, ChauMyThanh Tran, ThanhLoan Tran, Shang-Ling Pan
    Year: 2022

 

Conclusion

Dr. Son’s research plays a crucial role in advancing molecular biology by identifying key biomarkers and regulatory networks for disease screening and treatment. His work in gene-targeted therapy and RNA interaction networks lays the groundwork for future innovations in precision medicine. Despite challenges in resources and time, his commitment to molecular research aims to drive further advancements in understanding and treating complex diseases.

Kawthar Diab | Life Science | Best Researcher Award

Kawthar Diab | Life Science | Best Researcher Award

Prof. Dr. Kawthar Diab, National Research Centre, Egypt.

Dr. Kawthar Abdelaziz Elsayed Mohamed Diab is a distinguished Research Professor in Genetics and Cytology at the National Research Centre, Cairo, Egypt. With a strong foundation in zoology, she pursued advanced degrees focusing on genotoxicity, cytogenetics, and medicinal plant applications in disease prevention. Her postdoctoral research at Tokai University, Japan, and the Indian Institute of Integrative Medicine, India, expanded her expertise in cancer pharmacology and bioscience. Dr. Diab has made significant contributions to genetic toxicology and the chemopreventive properties of medicinal plants, with a particular focus on the Lamiaceae family and Himalayan plants. She actively mentors Ph.D. students and collaborates on groundbreaking research projects, gaining international recognition through conferences and workshops.

Profile

Google Scholar

Scopus

🌱 Early Academic Pursuits

Kawthar Abdelaziz Elsayed Mohamed Diab embarked on her academic journey with a deep passion for zoology, earning her B.Sc. in Zoology from Al-Azhar University in 1996 with a distinguished grade of “Very Good.” She further honed her expertise by obtaining an M.Sc. in Experimental Zoology from Zagazig University in 2003, where she conducted cytogenetic and immunogenetic studies on the effects of chemotherapy drugs on reproduction. Her academic curiosity and dedication led her to pursue a Ph.D. in Zoology at Ain Shams University, awarded in 2009. Her doctoral research focused on the protective effects of medicinal plants against genotoxic damage induced by hydrocortisone in mice, marking the beginning of her lifelong commitment to genetic research and cytology.

🧬 Professional Endeavors

As a Research Professor at the Genetics and Cytology Department of the National Research Centre in Cairo, Egypt, Dr. Kawthar Diab has played a pivotal role in advancing genetic studies. Her postdoctoral fellowships further expanded her scientific horizons—first in Cancer Pharmacology at the Indian Institute of Integrative Medicine in 2012 and later in Bioscience at Tokai University, Japan, in 2014. These international research experiences enriched her expertise in genetic applications, cytogenetics, and pharmacogenomics. Her relentless pursuit of knowledge has positioned her as a leading researcher in genetic and cytological studies, bridging traditional knowledge with cutting-edge scientific advancements.

🌿 Contributions and Research Focus

Dr. Diab’s research delves into the genotoxicity of pharmaceutical compounds and the protective effects of medicinal plants. Her investigations focus on the genetic impact of chemotherapy drugs and natural therapeutic agents, particularly those derived from the Lamiaceae family, known for their biochemical and therapeutic properties. Her recent supervision of Ph.D. research on biochemical and therapeutic evaluations of medicinal plants for prostate diseases underscores her commitment to integrating molecular genetics with natural medicine. Additionally, her work on cancer chemoprevention using Himalayan plants has gained international recognition, reflecting her dedication to discovering novel plant-based remedies for serious health conditions.

🌍 Accolades and Recognition

Dr. Kawthar Diab’s expertise has been acknowledged on the global stage. She was invited as a speaker at the 6th Rajabhat University National and International Research and Academic Conference (2020), where she presented her groundbreaking research on cancer chemopreventive activity of Himalayan plants. She has also participated in esteemed international workshops, including the Fluorescence Microscopy Workshop at ICGEB, New Delhi (2019), further enhancing her methodological skills. These recognitions highlight her contributions to genetic research and her growing influence in the scientific community.

📖 Impact and Influence

Beyond her research, Dr. Diab is actively shaping the next generation of scientists. She mentors young researchers, including Ph.D. students working on innovative projects in pharmacogenomics and plant-based medicine. Her collaboration with interdisciplinary teams ensures that her work extends beyond academic publications, making real-world contributions to medical science and genetics. By fostering a culture of inquiry and scientific exploration, she continues to inspire budding researchers to explore the genetic foundations of disease prevention and treatment.

🔬 Legacy and Future Contributions

With a research portfolio spanning genetic toxicology, medicinal plant applications, and cytogenetics, Dr. Kawthar Diab’s legacy is firmly established in the scientific world. She envisions a future where genetic research and plant-based therapeutics converge to provide safer, more effective treatments for cancer and genetic disorders. Her continuous engagement with international scientific platforms and her mentorship of emerging scholars ensure that her influence will extend far beyond her own research, shaping the future of genetic and cytological studies.

Publication

  • Title: In Vitro Anticancer Activities of Anogeissus latifolia, Terminalia bellerica, Acacia catechu and Moringa oleifera Indian Plants
    Author: KAE Diab, SK Guru, S Bhushan, AK Saxena
    Year: 2015

 

  • Title: In vitro studies on phytochemical content, antioxidant, anticancer, immunomodulatory, and antigenotoxic activities of lemon, grapefruit, and mandarin citrus peels
    Author: KAE Diab
    Year: 2016

 

  • Title: In vivo comparative studies on antigenotoxicity of date palm (Phoenix dactylifera L.) pits extract against DNA damage induced by N-Nitroso-N-methylurea in mice
    Author: KA Diab, EI Aboul-Ela
    Year: 2012

 

  • Title: Carbon tetrachloride induced hepato/renal toxicity in experimental mice: antioxidant potential of Egyptian Salvia officinalis L essential oil
    Author: MA Fahmy, KA Diab, NS Abdel-Samie, EA Omara, ZM Hassan
    Year: 2018

 

  • Title: Genotoxicity of carbon tetrachloride and the protective role of essential oil of Salvia officinalis L. in mice using chromosomal aberration, micronuclei formation, and …
    Author: KAE Diab, MA Fahmy, ZM Hassan, EM Hassan, AB Salama, EA Omara
    Year: 2018

 

  • Title: Inhibitory activity of black mulberry (Morus nigra) extract against testicular, liver and kidney toxicity induced by paracetamol in mice
    Author: KA Diab, MA Fahmy, EM Hassan, ZM Hassan, EA Omara, …
    Year: 2020

 

  • Title: The impact of the low frequency of the electromagnetic field on human
    Author: KA Diab
    Year: 2020

 

  • Title: Inhibitory activity of flaxseed oil against CdCl2 induced liver and kidney damage: Histopathology, genotoxicity, and gene expression study
    Author: KA Diab, NE Ibrahim, MA Fahmy, EM Hassan, EA Omara
    Year: 2020

🏆 Conclusion

Dr. Kawthar Diab’s journey from an aspiring zoologist to a distinguished Research Professor in Genetics and Cytology is a testament to her unwavering commitment to scientific discovery. Her work not only enhances our understanding of genetic toxicology but also paves the way for integrating traditional medicinal knowledge with modern genetic research. As she continues to push the boundaries of genetic science, her contributions remain invaluable to both academia and global health advancements.

Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst | Onco- Immunology | Best Researcher Award

Dr. Bastian Höchst,  Institute of Molecular Immunology, MRI, TUM, Germany.

Bastian Höchst is a distinguished molecular immunologist whose career spans groundbreaking research, impactful teaching, and valuable contributions to the scientific community. His academic journey began with a focus on biology and culminated in a doctorate on immune regulation in liver tumors. As a Research Group Leader at the Technical University of Munich, he investigates the complex interplay of immune cells and tissues in acute and chronic inflammation. His pioneering discoveries, such as the mechanisms governing myeloid suppressor cells and immune-regulatory metabolite transfer, have advanced understanding in the field.

Profile

Google Scholar

🌱 Early Academic Pursuits

Bastian Höchst began his academic journey with a passion for understanding the intricate mechanisms of biology. From 1999 to 2005, he pursued his studies in Biology at the University of Bonn and Hamburg, laying the foundation for his future endeavors in molecular immunology. His academic curiosity led him to pursue a doctorate at the Medical School Hannover under the guidance of Prof. Dr. Tim F. Greten. His doctoral research focused on identifying and characterizing myeloid-derived suppressor cells in patients with hepatocellular carcinoma, marking the beginning of his impactful contributions to the field of immunology.

🔬 Professional Endeavors

Currently serving as a Research Group Leader at the Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University of Munich (TUM), Bastian Höchst has dedicated his career to unraveling the complexities of immune regulation. His journey in academia has been marked by significant roles, including his previous tenure as a Research Group Leader at the Institute for Animal Physiology and Immunology, Wissenschaftszentrum Weihenstephan, TUM. Additionally, his postdoctoral fellowship at the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn further honed his expertise in immune mechanisms.

🧪 Contributions and Research Focus

Bastian Höchst’s research delves into immune regulation within acute and chronic inflammatory processes, with a particular focus on tissue-specific mechanisms. He has made groundbreaking discoveries, including elucidating the pathways that govern the generation of myeloid suppressor cells in liver tumors. Furthermore, his innovative work revealed that the intercellular transfer of immune-regulatory metabolites is critical to T-cell effector functions. His research has significantly advanced the understanding of immune responses in disease contexts, bridging gaps in immunological knowledge.

🎓 Teaching and Mentorship

A dedicated educator, Bastian Höchst has been actively involved in teaching since 2010, inspiring students in life sciences programs at TUM. His lectures on topics such as onco-immunology, immune metabolism, and immunotherapy provide invaluable insights to aspiring scientists. Through lab courses on immune cell phenotyping and advanced techniques like spectral flow cytometry, he has empowered students with the skills to explore the complexities of immunology. His teaching contributions extend beyond knowledge dissemination, fostering a generation of critical thinkers and innovators.

📜 Accolades and Recognition

Bastian’s expertise has been recognized through his habilitation and venia legendi for Molecular Immunology, under the mentorship of Prof. Dr. Percy Knolle. His contributions as a scientific reviewer for prestigious journals like Hepatology, Journal of Hepatology, and Frontiers in Immunology further reflect his authority in the field. Additionally, his role in evaluating grant applications for the Deutsche Forschungsgemeinschaft (DFG) underscores his impact on shaping future research initiatives.

🌍 Impact and Influence

Through his research, teaching, and reviews, Bastian Höchst has left an indelible mark on the field of molecular immunology. His work not only uncovers critical mechanisms of immune regulation but also provides pathways for therapeutic advancements in inflammatory and tumor-related conditions. His contributions influence both scientific understanding and practical applications, addressing global challenges in health and disease management.

🌟 Legacy and Future Contributions

Bastian Höchst’s journey is one of passion, discovery, and impact. As he continues to lead groundbreaking research, he sets the stage for a future where immune-based therapies are revolutionized. His legacy lies in his ability to connect fundamental research with real-world applications, inspiring colleagues and mentees alike. With his unwavering commitment to scientific exploration, Bastian Höchst is poised to shape the future of molecular immunology, paving the way for transformative breakthroughs.

Publication

  • A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells
    Authors: B. Höchst, L.A. Ormandy, M. Ballmaier, F. Lehner, C. Krüger, M.P. Manns, …
    Year: 2008

 

  • Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    Authors: B. Höchst, T. Voigtlaender, L. Ormandy, J. Gamrekelashvili, F. Zhao, …
    Year: 2009

 

  • Functional classification of memory CD8+ T cells by CX3CR1 expression
    Authors: J.P. Böttcher, M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Höchst, …
    Year: 2015

 

  • Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
    Authors: B. Höchst, J. Gamrekelashvili, M.P. Manns, T.F. Greten, F. Korangy
    Year: 2011

 

  • S100A9 a new marker for monocytic human myeloid‐derived suppressor cells
    Authors: F. Zhao, B. Höchst, A. Duffy, J. Gamrekelashvili, S. Fioravanti, M.P. Manns, …
    Year: 2012

 

  • Regulatory myeloid cells paralyze T cells through cell–cell transfer of the metabolite methylglyoxal
    Authors: T. Baumann, A. Dunkel, C. Schmid, S. Schmitt, M. Hiltensperger, K. Lohr, …
    Year: 2020

 

  • Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS
    Authors: D. Yuan, S. Huang, E. Berger, L. Liu, N. Gross, F. Heinzmann, M. Ringelhan, …
    Year: 2017

 

  • Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Authors: T.F. Greten, L.A. Ormandy, A. Fikuart, B. Höchst, S. Henschen, M. Hörning, …
    Year: 2010

 

Conclusion

Bastian Höchst’s career exemplifies dedication to advancing molecular immunology through innovative research, education, and mentorship. His contributions have shaped the understanding of immune responses in disease contexts, offering hope for novel therapeutic approaches. As he continues to lead impactful research and foster new talent, Bastian Höchst remains a visionary in his field, poised to drive future breakthroughs that bridge science and medicine for the benefit of society.

 

Gan Liu | Gastrointestinal cancer| Best Researcher Award | 1358

Mr. Gan Liu | Gastrointestinal cancer| Best Researcher Award

Mr. Gan Liu, the Affiliated Hospital of Qingdao University, China.

liu gan is a dedicated researcher and educator at qingdao university, specializing in gastric cancer diagnostics and treatment. his academic journey laid the foundation for innovative contributions to medical imaging and surgical oncology. through groundbreaking work in radiomics and robotic surgery, he has advanced diagnostic precision and surgical outcomes, significantly influencing global oncology practices. his achievements have garnered widespread recognition, marking him as a leader in his field.

 

profile

Scopus

🎓 early academic pursuits

liu gan began his academic journey with a strong foundation in medical sciences, focusing on the complexities of gastric cancer. his early education laid the groundwork for a career driven by curiosity and precision. by immersing himself in medical imaging and oncology, liu honed the skills necessary for innovative research. his dedication to learning and his commitment to advancing healthcare positioned him as a rising scholar in his field.

💼 professional endeavors

liu’s career flourished at qingdao university, where he took on pivotal roles in medical research and education. as a leading figure in oncology, he collaborated with multidisciplinary teams to develop advanced diagnostic and treatment protocols for gastric cancer. his expertise in medical imaging, particularly enhanced ct and radiomics, underscored his dedication to leveraging technology for better patient outcomes.

🔬 contributions and research focus

liu gan’s research centers on improving diagnostic precision and surgical outcomes for gastric cancer patients. he played a critical role in developing a deep learning radiomics nomogram to predict the response of metastatic lymph nodes to neoadjuvant chemotherapy. his investigations into robotic and laparoscopic total gastrectomy have provided valuable insights into optimizing surgical techniques, contributing significantly to evidence-based practice in oncology.

🏆 accolades and recognition

liu’s groundbreaking work has earned him accolades in both national and international academic circles. his contributions to gastric cancer research have been celebrated through awards, publications, and invitations to prestigious conferences. his role as a thought leader in medical imaging and oncology has cemented his reputation as a pioneer in his field.

🌍 impact and influence

liu’s work has transformed the understanding and management of gastric cancer, impacting clinical practice and patient care globally. his innovative approaches to medical imaging and surgery have set new standards in oncology. by combining technology with medical expertise, liu has influenced a new generation of researchers and clinicians, inspiring advancements in cancer treatment.

✨ legacy and future contributions

as a dedicated researcher and educator, liu gan’s legacy is one of innovation and excellence. his work continues to inspire future medical breakthroughs, with ongoing projects poised to revolutionize gastric cancer diagnostics and treatments. his vision for integrating artificial intelligence into oncology holds promise for reshaping the future of cancer care.

📚 Publications

  1. Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: A single-center retrospective propensity score matching study
    Authors: Liu, G., Cao, S., Liu, X., Wang, K., Zhou, Y.
    Year: 2025

 

  1. Deep Learning Radiomics Nomogram Based on Enhanced CT to Predict the Response of Metastatic Lymph Nodes to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
    Authors: Zhong, H., Wang, T., Hou, M., Liu, Z., Zhou, Y.
    Year: 2024

 

  1. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis
    Authors: Zhong, H., Liu, X., Tian, Y., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Intraoperative performance and outcomes of robotic and laparoscopic total gastrectomy for gastric cancer: A high-volume center retrospective propensity score matching study
    Authors: Jia, Z., Cao, S., Meng, C., Wang, Q., Zhou, Y.
    Year: 2023

 

  1. Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial
    Authors: Liu, G., Cao, S., Liu, X., Zhong, H., Zhou, Y.
    Year: 2022

 

  1. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: a randomized controlled trial
    Authors: Liu, D., Jing, X., Cao, S., Liu, G., Zhou, Y.
    Year: 2021

 

  1. Overexpression of tumour necrosis factor-α induced protein 8 is associated with prognosis in colon cancer
    Authors: Zhang, X., Li, Z., Sun, Y., Liu, X., Zhou, Y.
    Year: 2021

 

  1. Short- and long-term outcomes associated with enhanced recovery after surgery protocol vs conventional management in patients undergoing laparoscopic gastrectomy
    Authors: Tian, Y.-L., Cao, S.-G., Liu, X.-D., Wang, D.-S., Zhou, Y.-B.
    Year: 2020

Conclusion

liu gan’s legacy reflects a profound commitment to enhancing cancer care through research and innovation. his integration of cutting-edge technologies like artificial intelligence into clinical oncology paves the way for future breakthroughs. by inspiring the next generation of medical professionals and driving impactful healthcare solutions, liu’s work ensures lasting progress in the fight against gastric cancer.